Meeks is the Edward M. Schaeffer, MD, PhD Professor of Urology and associate professor of urology, biochemistry, and molecular genetics at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Expert discusses the NMIBC trials landscape
"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
“It's going to be an important time for US urologists to identify that this is becoming the standard of care," says Joshua J. Meeks, MD, PhD.
Expert describes implications of neoadjuvant durvalumab approval in MIBC
"There really wasn't a difference in in surgical outcomes. The patients tolerated it very well,” says Joshua J. Meeks, MD, PhD.
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
“The NIAGARA approval really begins to bring immunotherapy into the neoadjuvant setting," says Joshua J. Meeks, MD, PhD.
Pembrolizumab plus axitinib shows sustained benefit vs sunitinib in ccRCC
Phase 1/2 trial of INKmune therapy for mCRPC meets primary end point
How to bill for mitomycin for intravesical solution in NMIBC
Biopsy grade alone may underestimate risk in GG1 prostate cancer